Stock KROS KEROS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
56.39 USD -3.80% Intraday chart for Keros Therapeutics, Inc. +2.17% +41.83%
Mar. 19 Morphic Holding Names Simon Cooper as Chief Medical Officer MT
Mar. 15 Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug MT

Evolution of the average Target Price on Keros Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b300afbe146be88b3f750.VAuQs4iWVKE9Fx2dK4xjf61yLZcvUjR6m9Gm8qXvXbY.ED292PrlDuAEYmz4bb8VHPkDW_0fN2wTr6P3ncmiDYIdXOT73dNs7Ahibg~60ab31453982ab0bdffd4ef6fad51bb7

Analyst Recommendations on Keros Therapeutics, Inc.

Wedbush Starts Keros Therapeutics at Outperform With $86 Price Target MT
BofA Securities Initiates Keros Therapeutics With Buy Rating, $65 Price Target MT
BofA Securities Starts Keros Therapeutics at Buy With $65 Price Target MT
Piper Sandler Adjusts Keros Therapeutics' Price Target to $110 From $120, Keeps Overweight Rating MT
Cowen Starts Keros Therapeutics at Outperform MT
BTIG Adjusts Price Target on Keros Therapeutics to $105 From $95, Maintains Buy Rating MT
Truist Securities Starts Keros Therapeutics at Buy With $100 Price Target MT
BTIG Initiates Coverage on Keros Therapeutics With Buy Rating, $80 Price Target MT
Piper Sandler Adjusts Keros Therapeutics' Price Target to $120 from $90, Keeps Overweight Rating MT
KEROS THERAPEUTICS : Jefferies Adjusts Keros Therapeutics PT to $75 From $70, Maintains Buy Rating MT
KEROS THERAPEUTICS : Piper Sandler Adjusts Keros Therapeutics' Price Target to $95 From $75, Reiterates Overweight Rating MT
KEROS THERAPEUTICS : HC Wainwright Adjusts Keros Therapeutics' Price Target to $100 From $50, Keeps at Buy MT
KEROS THERAPEUTICS : SVB Leerink Adjusts Keros Therapeutics' Price Target to $80 from $42, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
58.62 USD
Average target price
88.11 USD
Spread / Average Target
+50.31%
High Price Target
105 USD
Spread / Highest target
+79.12%
Low Price Target
77 USD
Spread / Lowest Target
+31.35%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Keros Therapeutics, Inc.

Wedbush
BofA Securities
Piper Sandler
Cowen
BTIG
Truist Securities

Ratings for Keros Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. KROS Stock
  4. Consensus Keros Therapeutics, Inc.